A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer
A Phase 1, Open-Label, Multi-center, Dose Escalation Study of the Safety and Pharmacokinetics of AGS-16M18 Given as Monotherapy in Subjects With Advanced Renal Cell Carcinoma
Sponsor: Agensys, Inc.
Terminated
Trial was terminated due to the need to re-formulate the study drug.
Other terminated trials from Agensys, Inc.
More terminations from Agensys, Inc.
Other Carcinoma, Renal Cell trials with similar outcome
Listed as NCT00816686, this PHASE1 trial focuses on Carcinoma, Renal Cell and Kidney Diseases and remains terminated or withdrawn. Sponsored by Agensys, Inc., it has been updated 6 times since 2008, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Oct 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Agensys, Inc.
- Astellas Pharma Inc
For direct contact, visit the study record on ClinicalTrials.gov .